Analysts Estimate Icon PLC (ICLR) to Report a Decline in Earnings: What to Look Out for

Icon PLC (ICLR) is anticipated to report a significant year-over-year decline for the quarter ended June 2025, with consensus estimates projecting EPS to fall 15.2% to $3.18 and revenues to decrease 6.4% to $1.98 billion. Despite a history of beating EPS estimates in three of the last four quarters, Zacks analysis indicates a negative Earnings ESP of -1.38% combined with a Zacks Rank of #3, making it difficult to conclusively predict an earnings beat for the upcoming July 23 release and suggesting it is not a compelling earnings-beat candidate.

Analysis

Icon PLC (ICLR) is positioned for a challenging quarter, with consensus estimates for its upcoming June 2025 report pointing to a significant year-over-year contraction. Projections indicate a 15.2% decline in earnings per share to $3.18 and a 6.4% decrease in revenue to $1.98 billion. While these estimates have been stable over the past 30 days, recent analyst sentiment appears to have turned more bearish, as reflected by a negative Zacks Earnings ESP of -1.38%. This metric, combined with a neutral Zacks Rank #3 (Hold), makes it difficult to conclusively predict an earnings beat and suggests the company is not a compelling candidate for an upside surprise. This outlook is notable given ICLR's history of surpassing EPS estimates in three of the last four quarters. Furthermore, the company's expected decline contrasts with peer Medpace (MEDP), which is forecast to report YoY growth in both revenue (+2.5%) and earnings (+9.1%), suggesting potential company-specific headwinds for ICLR rather than a broader industry downturn.

Key Decisions for Investors

• Given the consensus for a double-digit earnings decline and a negative Earnings ESP, investors should exercise caution and consider managing downside risk ahead of the July 23 report.
• Focus should extend beyond the headline EPS and revenue figures to management's forward-looking guidance on the earnings call, as this will be critical in determining the stock's sustainable direction.
• The performance divergence between ICLR's expected decline and peer Medpace's forecasted growth warrants a review of ICLR's positioning relative to competitors in the medical services sector.